Patent Assignment
Reel/Frame 048380/0009
Change of Name
Recorded: 2018-12-07
Pages: 14
Assignor
RXI PHARMACEUTICALS CORPORATION
Executed: 2018-11-14
Assignee
PHIO PHARMACEUTICALS CORP.
257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MASSACHUSETTS, 01752
Covered Properties
(85)
Minimum Length Triggers of Rna Interference
Application:
61/149,946 →
Minimum Length Triggers of Rna Interference
Application:
61/224,031 →
Reduced Size Self-Delivering Rnai Compounds
Ps Tail Constructs for Rna Delivery and Functionality
Application:
61/149,968 →
Ps Tail Constructs for Rna Delivery and Functionality
Application:
61/150,582 →
Rna Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
Application:
61/163,306 →
Rna Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
Macrophage drug delivery system
Application:
61/135,244 →
Short hairpin RNAi constructs and uses thereof
Application:
61/135,855 →
miniRNA constructs and uses thereof
Application:
61/197,768 →
RNAi constructs and uses thereof
Application:
61/208,394 →
RNAi constructs and uses thereof
Application:
61/209,429 →
Rnai Constructs and Uses Thereof
Application:
13/055,617 →
Publication:
US 2011/0251258
Novel Compositions of Chemically Modified Small Interfering Rna
Application:
12/227,893 →
Publication:
US 2010/0069620
Modified RNAi polynucleotides and uses thereof
Application:
61/065,335 →
Modified Rnai Polynucleotides and Uses Thereof
Inhibition of MAP4K4 through RNAI
Application:
61/199,661 →
Inhibition of MAP4K4 Through Rnai
Inhibition of PCSK9 through RNAI
Application:
61/204,348 →
Inhibition of PCSK9 Through Rnai
Inhibition of PCSK9 Through Rnai
Application:
16/191,396 →
Publication:
US 2019/0218557
Tripartite RNAi Constructs
Application:
60/976,855 →
Tripartite RNAi constructs
Application:
12/286,896 →
Publication:
US 2009/0131360
Energy-Activated RNAi Constructs
Application:
60/976,858 →
Rna Interference in Skin Indications
Neutral Nanotransporters
Formulations and Methods for Targeted Delivery to Phagocyte Cells
Application:
61/310,611 →
Reduced Size Self-Delivering Rnai Compounds
Application:
61/317,261 →
Reduced Size Self-Delivering Rnai Compounds
Application:
61/317,597 →
Reduced Size Self-Delivering Rnai Compounds
Rna Interference in Ocular Indications
Application:
61/317,254 →
Rna Interference in Ocular Indications
Application:
61/317,621 →
Rna Interference in Skin Indications
Application:
61/317,252 →
Rna Interference in Skin Indications
Application:
61/317,633 →
Rna Interference in Dermal and Fibrotic Indications
Reduced Size Self-Delivering Rnai Compounds
Methods for Early Treatment of Wound Healing Utilizing Chemically Modified Oligonucleotides
Application:
61/911,991 →
Methods for Treatment of Wound Healing Utilizing Chemically Modified Oligonucleotides
Application:
62/049,299 →
Methods for Treatment of Wound Healing Utilizing Chemically Modified Oligonucleotides
Application:
15/101,770 →
Publication:
US 2016/0304875
Methods for Accelerating Wound Healing Utilizing Chemically Modified Oligonucleotides
Application:
61/911,993 →
Methods for Treating Cancer Using Nucleic Acids Targeting MDM2 or Mycn
Application:
61/985,446 →
Methods for Treating Cancer Using Nucleic Acids Targeting MDM2 or Mycn
Methods for Treatment of Disorders in the Front of the Eye Utilizing Nucleic Acid Molecules
Application:
61/987,418 →
Methods for Treatment of Disorders in the Front of the Eye Utilizing Nucleic Acid Molecules
Application:
15/307,529 →
Publication:
US 2017/0051290
Methods for Treating Aging and Skin Disorders Using Nucleic Acids Targeting Tyr or MMP1
Application:
62/046,523 →
Methods for Treating Aging and Skin Disorders Using Nucleic Acids Targeting Tyr or Mmpi
Application:
62/047,972 →
Methods for Treating Aging and Skin Disorders Using Nucleic Acids Targeting Tyr or MMP1
Application:
62/102,287 →
Methods for Treating Aging and Skin Disorders Using Nucleic Acids Targeting Tyr or MMP1
Methods for the Treatment of Alopecia Areata Utilizing Gene Modulation Approaches
Application:
62/087,138 →
Methods for the Treatment of Alopecia Areata Utilizing Gene Modulation Approaches
Application:
62/095,309 →
Methods for the Treatment of Alopecia Areata Utilizing Gene Modulation Approaches
Application:
15/532,804 →
Publication:
US 2018/0263925
Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition for the Treatment of Warts
Application:
61/309,717 →
Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition
Application:
13/035,692 →
Publication:
US 2011/0268761
Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition
Gelled immunomodulating topical compositions and a method of treating warts and other human papilloma virus skin infections
Application:
11/228,569 →
Publication:
US 2006/0211766
Nucleic Acid Molecules Targeting Superoxide Dismutase 1 (SOD1)
Application:
62/189,050 →
Nucleic Acid Molecules Targeting Superoxide Dismutase 1 (SOD1)
Methods for Treating Neurological Disorders Using a Synergistic Small Molecule and Nucleic Acids Therapeutic Approach
Application:
62/189,142 →
Methods for Treating Neurological Disorders Using a Synergistic Small Molecule and Nucleic Acids Therapeutic Approach
Methods for Treating Skin Disorders and Conditions Utilizing Haptens
Application:
62/217,683 →
Methods for Treating Skin Disorders and Conditions Utilizing Haptens
Application:
62/262,871 →
Topical Immunomodulating Compositions for Treatment of Aids and Other Immunocompromised Diseases
Application:
60/112,363 →
Reduced Size Self-Delivering Nucleic Acid Compounds Targeting Long Non-Coding Rna
Application:
62/243,565 →
Immunotherapy of Cancer
Application:
61/910,728 →
Immunotherapy of Cancer
Topical Delivery of Nucleic Acid Compounds
Application:
62/487,454 →
Immunotherapy of Cancer Utilizing Chemically Modified Oligonucleotides
Application:
62/542,043 →
Control of Differentiation Utilizing Chemically Modified Oligonucleotides in Immunotherapy
Application:
62/558,183 →
Reduced Size Self-Delivering Rnai Compounds
Reduced Size Self-Delivering Rnai Compounds
Rna Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
Phagocytic Cell Delivery of Rnai
Modified Rnai Polynucleotides and Uses Thereof
Inhibition of MAP4K4 Through Rnai
Inhibition of PCSK9 Through Rnai
Rna Interference in Skin Indications
Rna Interference in Skin Indications
Rna Interference in Skin Indications
Neutral Nanotransporters
Reduced Size Self-Delivering Rnai Compounds
Rna Interference in Ocular Indications
Rna Interference in Dermal and Fibrotic Indications
Rna Interference in Dermal and Fibrotic Indications
Reduced Size Self-Delivering Rnai Compounds
Topical Immunomodulating Compositions for Treatment of Aids, Hepatitis B&C, Other Infectious Diseases, and Cancer
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 2, 2008
From: PAVCO, PAM; NIEWOOD, JOANNE; WOOLF, TOD; SALOMON, WILLIAM
To: RXI PHARMACEUTICALS CORP.
Reel/Frame 021190/0968 →
Assignment of Assignor's Interest
Jul 3, 2008
From: WOOLF, TOD; PAVCO, PAM; SALOMON, WILLIAM; USMAN, NASSIM
To: RXI PHARMACEUTICALS CORP.
Reel/Frame 021197/0242 →
Assignment of Assignor's Interest
Dec 2, 2008
From: WOOLF, TOD M.; WAGNER, RICK
To: RXI PHARMACEUTICALS CORP.
Reel/Frame 021917/0165 →
Assignment of Assignor's Interest
Jan 27, 2009
From: WOOLF, TOD M.; PAVCO, PAMELA A.; SALOMON, WILLIAM; SAMARSKY, DMITRY
To: RIX PHARMACEUTICALS CORP.
Reel/Frame 022186/0091 →
Assignment of Assignor's Interest
Mar 10, 2009
From: WOOLF, TOD; SALOMON, WILLIAM; KAMENS, JOANNE; KHVOROVA, ANASTASIA
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 022371/0776 →
Assignment of Assignor's Interest
Mar 10, 2009
From: WOOLF, TOD; KAMENS, JOANNE; SALOMON, WILLIAM; KHVOROVA, ANASTASIA
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 022371/0821 →
Assignment of Assignor's Interest
Apr 17, 2009
From: SAMARSKY, DMITRY
To: RXI PHARMACEUTICALS CORP.
Reel/Frame 022565/0292 →
Assignment of Assignor's Interest
Apr 20, 2009
From: KAMENS, JOANNE
To: RXI PHARMACEUTICALS CORP.
Reel/Frame 022569/0560 →
Assignment of Assignor's Interest
May 6, 2009
From: SAMARSKY, DMITRY
To: RXI PHARMACEUTICALS CORP.
Reel/Frame 022648/0394 →
Assignment of Assignor's Interest
May 8, 2009
From: SAMARSKY, DMITRY; WOOLF, TOD M.
To: RXI PHARMACEUTICALS CORP.
Reel/Frame 022666/0091 →
Assignment of Assignor's Interest
Sep 28, 2009
From: SAMARSKY, DMITRY; WOOLF, TOD M.; KAMENS, JOANNE; KHVOROVA, ANASTASIA
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 023290/0035 →
Assignment of Assignor's Interest
Sep 28, 2009
From: SALOMON, WILLIAM; KAMENS, JOANNE; KHVOROVA, ANASTASIA; SAMARSKY, DMITRY
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 023290/0165 →
Assignment of Assignor's Interest
Nov 5, 2010
From: SALOMON, WILLIAM; KAMENS, JOANNE; KHVOROVA, ANASTASIA; SAMARSKY, DMITRY
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 025327/0870 →
Assignment of Assignor's Interest
Feb 9, 2011
From: BULOCK, KAREN; KHVOROVA, ANASTASIA; LAPIERRE, JENNIFER
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 025774/0813 →
Assignment of Assignor's Interest
Feb 16, 2011
From: KHVOROVA, ANASTASIA; SALOMON, WILLIAM; KAMENS, JOANNE; SAMARSKY, DMITRY
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 025814/0853 →
Assignment of Assignor's Interest
Feb 16, 2011
From: KHVOROVA, ANASTASIA; SALOMON, WILLIAM; KAMENS, JOANNE; SAMARSKY, DMITRY
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 025816/0119 →
Security Agreement
Sep 26, 2011
From: RNCS, INC.
To: TANG CAPITAL PARTNERS, LP
Reel/Frame 026976/0187 →
Assignment of Assignor's Interest
Sep 26, 2011
From: RXI PHARMACEUTICALS CORPORATION
To: RNCS, INC.
Reel/Frame 026969/0660 →
Change of Name
Sep 29, 2011
From: RNCS, INC.
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 026988/0874 →
Assignment of Assignor's Interest
Oct 26, 2011
From: SAMARSKY, DMITRY; WOOLF, TOD M.; SALOMON, WILLIAM; KAMENS, JOANNE
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 027126/0511 →
Assignment of Assignor's Interest
Jan 13, 2012
From: KAMENS, JOANNE; SALOMON, WILLIAM; KHVOROVA, ANASTASIA; WOOLF, TOD M.
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 027529/0459 →
Assignment of Assignor's Interest
Jan 19, 2012
From: WOOLF, TOD M.; KAMENS, JOANNE; KHVOROVA, ANASTASIA; SALOMON, WILLIAM
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 027558/0025 →
Assignment of Assignor's Interest
Jan 19, 2012
From: SAMARSKY, DMITRY; SALOMON, WILLIAM; KAMENS, JOANNE; KHVOROVA, ANASTASIA
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 027558/0142 →
Release of Security Interest
May 2, 2012
From: TANG CAPITAL PARTNERS, LP
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 028144/0110 →
Assignment of Assignor's Interest
Jul 31, 2015
From: KHVOROVA, ANASTASIA; SALOMON, WILLIAM; KAMENS, JOANNE; SAMARSKY, DMITRY
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 036239/0114 →